GENE ONLINE|News &
With New Funding, ACELYRIN Licenses First Therapeutic and Leaps into Late-Stage Trials for Autoimmune Diseases
Los Angeles-based ACELYRIN, Inc. takes a different approach to drug development. They create a portfolio by identifying, licensing, acquiring, or partnering with companies to rapidly create a therapeutic portfolio. By rapidly assembling teams, funding, and resources, they aim to accelerate the development and commercialization of promising therapeutics.
Founded in 2020 by Dr. Shao-Lee Lin and Robert F. Carey, now the CEO and President respectively, ACELYRIN launched after raising $8 million from Westlake Village BioPartners. Their goal was to target clinical-stage programs with an initial focus is on immunology.
Not even a year after their creation, ACELYRIN has announced it raised a quarter of a billion dollars, and it licensed its first therapeutic. With this, they officially launch their pipeline.
Founded in 2020 by Dr. Shao-Lee Lin and Robert F. Carey, now the CEO and President respectively, ACELYRIN launched after raising $8 million from Westlake Village BioPartners. Their goal was to target clinical-stage programs with an initial focus is on immunology.
Not even a year after their creation, ACELYRIN has announced it raised a quarter of a billion dollars, and it licensed its first therapeutic. With this, they officially launch their pipeline.
